A patient in a phase 2 trial has received the first dose of a novel combination of botensilimab and balstilimab plus agenT-979, an allogeneic cell therapy.
Imfinzi plus chemotherapy, when given before surgery, improved pathologic complete response rates, regardless of region, in certain patients with gastric or gastroesophageal junction cancers.
Kai-Keen Shiu, MD, discusses the significance of the FDA approval of pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment in patients with locally advanced, unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.
The combination of domvanalimab, zimberelimab, and FOLFOX elicited responses in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, irrespective of PD-L1 status